These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 34969692

  • 1. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
    Hougen I, Whitlock RH, Komenda P, Rigatto C, Clemens KK, Tangri N.
    BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34969692
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z.
    JAMA Intern Med; 2021 Aug 01; 181(8):1043-1053. PubMed ID: 34180939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH, Man KKC, Shi M, Chan EW, Ho CW, Tse ETY, Wong ICK, Lam CLK.
    PLoS Med; 2019 Dec 01; 16(12):e1002999. PubMed ID: 31877127
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May 01; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 11. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.
    PLoS One; 2015 May 01; 10(5):e0124287. PubMed ID: 25992614
    [Abstract] [Full Text] [Related]

  • 12. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.
    JAMA Intern Med; 2014 Dec 01; 174(12):1955-62. PubMed ID: 25347323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
    Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.
    Drugs Aging; 2008 Dec 01; 25(7):611-22. PubMed ID: 18582148
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.